ImmunoGen Announces Webcasts of Presentations at Upcoming Virtual Conferences
ImmunoGen, Inc. (Nasdaq: IMGN) has announced its participation in two upcoming investor conferences, highlighting its leadership in antibody-drug conjugates for cancer treatment. The first event is the Piper Sandler 32nd Annual Virtual Healthcare Conference on November 23 at 10:00 am ET, followed by the Evercore ISI Annual HealthCONx Conference on December 1 at 12:10 pm ET. Webcasts will be available on the company's website, with replays offered afterward. ImmunoGen focuses on developing targeted therapies to improve cancer patient outcomes.
- None.
- None.
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
-
Piper Sandler 32nd Annual Virtual Healthcare Conference
November 23 at 10:00am ET
-
Evercore ISI Annual HealthCONx Conference
December 1 at 12:10pm ET
A webcast of each presentation will be accessible through the Investors and Media section of the Company's website, www.immunogen.com. Following the live webcast, a replay will be available at the same location.
ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to “target a better now.”
Learn more about who we are, what we do, and how we do it at www.immunogen.com.
